COMMUNIQUÉS West-GlobeNewswire
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
27/03/2024 -
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
27/03/2024 -
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
27/03/2024 -
Inventiva reports its 2023 full-year results
27/03/2024 -
Inventiva publie ses résultats annuels 2023
27/03/2024 -
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
27/03/2024 -
Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group
27/03/2024 -
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
27/03/2024 -
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version
27/03/2024 -
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27/03/2024 -
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement
27/03/2024 -
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27/03/2024 -
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
27/03/2024 -
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
27/03/2024 -
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
27/03/2024 -
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
27/03/2024 -
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
27/03/2024 -
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27/03/2024 -
Tevogen Bio Announces Series A-1 Preferred Stock Investment
27/03/2024
Pages